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Abstract: Extramammary Paget disease (EMPD) is a rare neo-
plasm usually presenting in the anogenital area, most commonly in
the vulva. Adnexal involvement in primary EMPD is a very common
feature and serves as a pathway for carcinoma to spread into deeper
tissue. The depth of carcinomatous spread along the appendages and
the patterns of adnexal involvement were studied in 178 lesions from
146 patients with primary EMPD. Hair follicles and eccrine ducts
were the adnexa most commonly affected by carcinoma cells. The
maximal depth of involvement was 3.6 mm in this series. When
planning topical therapy or developing novel local treatment
modalities for EMPD, this potential for signiﬁcant deep spread
along adnexa should be taken into account.
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INTRODUCTION
Extramammary Paget disease (EMPD) is a rare neo-
plasm usually presenting in the anogenital area, most
commonly in the vulva, where it represents approximately
1% of malignant lesions.1 EMPD can be divided into primary
and secondary variants, the latter representing intraepithelial
spread of an underlying carcinoma, usually from the urogen-
ital or gastrointestinal tracts.2–5
Primary EMPD is a form of intraepithelial adenocarci-
noma of uncertain histogenesis, for which cutaneous adnexa,
clear cells of Toker, pluripotent stem cells, and anogenital
mammary-like glands (AGMLG) have been proposed as
possible sites of origin.2,6–18
Surgical excision is a widely used treatment modality
for primary EMPD but this can be disﬁguring and recurrences
are not uncommon. Other than surgery, in recent years,
topical drugs such as imiquimod, 5-ﬂuorouracil, and retinoic
acid, alone or in combination, have been used for the
treatment of EMPD.19 The application of these drugs is based
on the premise that most primary EMPD represents a form of
adenocarcinoma in situ, in which a proliferation of the neo-
plastic cells is conﬁned to the epidermis or mucosal epithe-
lium and can be destroyed by the drug, either directly or
through immunoreactive processes. One can speculate, how-
ever, that in EMPD invading the underlying dermis, these
treatments would be less effective. In addition, previous case
reports and case series have demonstrated that adnexal
involvement is common in EMPD and that the adnexa may
serve as a pathway for carcinoma spreading to deeper tissues
where local therapeutic agents are less likely to be effec-
tive.7,20,21 Since the depth of adnexal involvement has never
been previously studied, our primary goal was to establish the
depth of spread of carcinomatous cells along the adnexa in
primary EMPD, and also to identify previously undescribed
patterns of adnexal involvement by studying 178 lesions from
146 patients with primary anogenital EMPD.
MATERIAL AND METHODS
Case Selection
A search in the consultation, routine institutional, and
personal ﬁles of the authors between 1993 and 2015 years
yielded 167 cases coded as EMPD. Histological slides were
reviewed along with the available clinical information
obtained from patients’ medical records to conﬁrm the
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location and the clinicopathological context. Only cases of
primary anogenital EMPD were included. Excluded from
the study were 21 cases of secondary EMPD arising from
carcinomas of other possible origins (rectum, urethra, pros-
tate, etc.) as well as cases with insufﬁcient clinical data.
Thus, the study cohort consisted of 178 specimens from
146 patients with primary anogenital EMPD.
Light Microscopy
The study was based on the assessment of hematoxylin
and eosin–stained slides, periodic acid-Schiff–stained and/or
mucicarmine-stained sections, and immunostains for cytoker-
atin 7. Of the 178 specimens, 99 were wide surgical exci-
sions, local resections, or vulvectomies (the number of tissue
blocks ranged from 1 to 59; median 10) and 79 were small
specimens (punch, or small incisional biopsies, with a single
block per case). From 13 patients, both primary and recurrent
tumors were available for study (1 recurrence in 8 patients;
2 recurrences in 4 patients; 3 recurrences in 1 patient).
Involvement of cutaneous adnexal structures including
hair follicles, sebaceous, apocrine, and eccrine glands and
their ducts were evaluated. Eccrine and apocrine ducts are
typically indistinguishable, but in many cases their nature
could be reasonably determined when they were clearly
related to an underlying apocrine or eccrine secretory coil
or acrosyringium (the intraepidermal part of the eccrine duct).
When it was not possible to distinguish between apocrine and
eccrine ducts, they were designated as “ducts, not otherwise
speciﬁed”. We also determined the presence and nature of
involvement of AGMLG and their ducts, but these results
will be the subject of a separate report.
Depth of invasion was determined on hematoxylin and
eosin–stained slides from large resection specimens only (n =
99), whereas for small specimens (n = 79), only the frequency
and distribution of adnexal involvement was documented. An
ocular micrometer was used to measure the depth from the sur-
face of the epidermis (corniﬁed layer) or epithelium to the deep-
est located tumor cell in an involved adnexal structure. In all
cases, we determined if there was microinvasion (deﬁned as
stromal invasion to a depth of no more than 1 mm below the
basement membrane22) or if depth of invasion exceeded 1 mm.
Twelve lesions were the subject of 2 previous reports.23,24
RESULTS
Clinical Data
The clinicopathological features of the 146 patients are
summarized in Table 1. There were 114 women and 32 men.
Age at diagnosis (known in 142 patients) ranged from 40 to
95 years (median, 73 years; mean, 71 years). In all but 1 case,
the lesions were solitary and occurred in the anogenital area
sometimes involving large areas (eg, vulva and perianal area;
scrotum and groin). One patient presented with bilateral groin
lesions. In women, EMPD most commonly involved the
vulva (89.4%) and less frequently the perianal (5.3%) regions.
In men, EMPD mostly involved the scrotum (40.6%) and
groin (25%). Thirteen patients had recurrences of EMPD. In
a further 2 patients with recurrent EMPD, the slides of the
original biopsies were not available for review. Clinically,
most lesions appeared as ﬂat or slightly elevated
TABLE 1. Main Clinical Characteristics of 146 Study Patients
Parameter N (%)
Age (yrs) 40–95 (median 73, mean 71.26)
Gender
Female 114 (78.1)
Male 32 (21.9)
Location
Genital 123 (84.2)
Vulva NOS or predominantly 93
Labium majus 8
Mons pubis 8
Scrotum (predominantly) 13
Periclitoral 1
Groin 10 (6.8)
Perianal 9 (6.2)
Anogenital, NOS 4 (2.7)
NOS, not otherwise speciﬁed. FIGURE 1. Clinical appearance of extramammary Paget dis-
ease: Erythematous erosive areas.
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erythematous or white-gray areas, with variable scaling, ex-
coriations, oozing, or crusting (Fig. 1).
Histopathological Findings
Of the 178 specimens, 165 were in situ EMPD and 13
were invasive EMPD. Of the latter, 9 were minimally
invasive, as deﬁned above, and 4 had dermal invasion
.1 mm in depth. Inguinal lymph node metastases occurred
in 1 case only.
Adnexal involvement was a common ﬁnding in large
samples (Table 2) as well as in small biopsy specimens
(Table 3). The most common targets were hair follicles,
involved in 92.8% of large resection specimens (91 of 98
TABLE 2. Frequency and Depth of Invasion of Adnexal
Structures in 99 Large Postoperative Specimens
Type of Adnexa
Involved/Present
(% with Involved
Adnexa); {Number/
% of Cases Where it
was the Deepest
Involved Structure}
Depth of Adnexal
Involvement in mm
Hair follicles 91/98 (92.8); {76/83.5} 0.5–3.25 (median
1.6, mean 1.64)
Sebaceous glands 29/79 (36.7); {1/3.4} 0.4–1.5 (median 1,
mean 0.98)
Eccrine secretory coil 12/95 (12.6); {5/41.7} 0.8–3.2 (median
2.55, mean 2.39)
Apocrine secretory coil 1/60 (1.7); {0} 1.8 (median 1.8,
mean 1.8)
Adnexal ducts
Eccrine ducts
Acrosyringium 87/89 (97.7)
Straight/coiled 54/76 (71.1); {13/24.1} 0.3–3.6 (median 1.1,
mean 1.28)
Apocrine ducts 6/41 (14.6); {0} 0.5–1.38 (median
0.93, mean 0.99)
Ducts, NOS 14/72 (19.4); {1/7.1} 0.4–2.5 (median
0.94, mean 0.98)
NOS, not otherwise speciﬁed.
TABLE 3. Frequency of Invasion of Adnexal Structures in 79
Small Biopsies Specimens
Type of Adnexa
Involved/Present (% With
Involved Adnexa)
Hair follicle 35/56 (62.5)
Sebaceous glands 5/23 (21.7)
Eccrine glands 1/44 (2.3)
Apocrine glands 1/9 (11.1)
Adnexal ducts
Eccrine ducts
Acrosyringium 23/26 (88.5)
Straight/coiled 7/21 (33.3)
Apocrine ducts 1/4 (25)
Ducts NOS 8/34 (23.5)
NOS, not otherwise speciﬁed.
FIGURE 2. Involvement of hair follicles in EMPD. Single tumor
cell infiltration and clusters of neoplastic cells involve a hair follicle
(A). Gland-like structures in hair follicles, some with cribriform
appearances, replacing most of native follicular epithelium (B).
Prominent involvement of hair follicle with comedonecrosis (C).
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specimens). In 76 large specimens (76.7%), the hair follicle
was the adnexal structure most deeply involved (compared
with sebaceous glands and apocrine or eccrine units). The
maximal depth of carcinoma cells affecting hair follicles
was 3.25 mm. In small biopsy specimens (n = 79), hair fol-
licles were present in more than half of the cases, of which
62.5% (35/56) were involved by Paget cells. In most cases,
neoplastic cells were dispersed in the affected hair follicles as
single cells or small clusters (Fig. 2A). Less commonly,
gland-like structures were formed (Fig. 2B). Whereas in most
cases only a minor proportion of the native follicular epithe-
lium was replaced by the neoplastic cells, a few cases dem-
onstrated extensive follicular involvement by the carcinoma,
sometimes accompanied by comedonecrosis (Fig. 2C).
Sebaceous glands were inﬁltrated by Paget cells in
a third of the large specimens and in a quarter of the small
biopsy samples. Both mature sebaceous glands and mantles
were seen to be involved by single cell spread or by small
groups of tumor cells (Fig. 3), sometimes identiﬁed only after
mucicarmine staining. The deepest involved sebaceous gland
was located 1.5 mm below the stratum corneum.
Involvement of eccrine units most frequently mani-
fested as inﬁltration of the acrosyringium (97.7%), which is
logical due to its intraepidermal location (Fig. 4). Intradermal
straight and coiled eccrine ducts were found in 76 large speci-
mens and were inﬁltrated by tumor cells in 54 samples
(71.1%) (Fig. 5), with the deepest involvement of 3.6 mm
seen in 13 specimens. In most, there was single cell inﬁltra-
tion of the ducts but small clusters of neoplastic cells and
gland-like structures were also noted less frequently (Fig.
6). Immature squamous cell metaplasia and hyperplasia of
duct epithelium were occasionally encountered, and a combi-
nation of metaplasia and hyperplasia resulted rarely in cribri-
form formations (Fig. 7). In some cases, neoplastic cells were
observed to have replaced mostly the basal/myoepithelial
cells with the focal preservation of luminal cells (Fig. 8).
The eccrine secretory coils were inﬁltrated less fre-
quently by tumor cells (12.6% of large specimens), in 4 cases
showing the deepest involvement to be at a maximal depth of
3.2 mm. Similar to other adnexal structures, eccrine glands
were seen to be colonized by single cells or groups of
neoplastic cells, and rarely by gland-like structures. In some
eccrine coils, complete replacement of the normal luminal
epithelium by solid or cribriform formations of Paget cells, in
the presence of preserved peripheral basal/myoepithelial cell
layers, occasioned a resemblance to either ductal carcinoma in
situ or so-called lobular cancerization as seen in mammary
carcinomas (Fig. 9).
FIGURE 3. Involvement of sebaceous glands in EMPD. Dispersed single tumor cells and small clusters in mature sebaceous glands
(A) and in the mantle (B).
FIGURE 4. Infiltration of the acrosyringium in EMPD.
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The apocrine secretory coils were involved in 14.6% of
cases, and never were they the deepest structure affected by
the carcinoma.
In 1 case, a large complex structure of uncertain
derivation was involved by neoplastic cells (Figs. 10, 11),
whereas in another case of recurrent EMPD involving the
neovulva, carcinoma cells colonized the remnants of a Bartho-
lin gland at a depth of 12 mm.
DISCUSSION
Our study validates the previously published observa-
tions that involvement of adnexa is a common feature in
primary EMPD, likely contributing to the spread of carci-
noma into deeper tissues and to the propensity for recur-
rence.7,18,20,21,25 Our study contributes novel data by
documenting the depth of adnexal involvement, hitherto not
previously examined. We found that Paget cells may spread
along the adnexa as deeply as 3.6 mm, with hair follicles and
eccrine ducts/glands being the most commonly and the most
deeply involved structures. This information should be taken
into account when planning topical nonsurgical treatment or
when developing new local treatment modalities in the future.
At present, imiquimod, 5-ﬂuorouracil, and retinoic acid are
used in the treatment of EMPD attempting to substitute for
alternative, often disﬁguring surgical approaches. Other novel
treatments including CO2 laser, trastuzumab, alone or in com-
bination with chemotherapy, and photodynamic therapy are
being studied.26–29 The above treatment modalities have dif-
fering mechanisms of action (eg, imiquimod acts as an
immune response modiﬁer; 5-ﬂuorouracil is a chemotherapeu-
tic agent; photodynamic therapy relies on light activation of
a photosensitizer in neoplastic cells) but the depth of skin
penetration and knowledge of the depths of tumor deposits
FIGURE 5. Involvement of the straight
portion of eccrine duct in EMPD, mostly
occurring as single cell colonization
(A, B).
FIGURE 6. Gland-like structures in an involved eccrine duct
(arrow).
FIGURE 7. Carcinoma cell infiltration of an eccrine duct,
which also shows squamous metaplasia and hyperplasia re-
sulting in a cribriform appearance.
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are obviously essential for planning successful treatment.
From our literature review, we have been unable to determine
to what depth imiquimod may penetrate the skin, whereas
5-ﬂuorouracil reportedly penetrates the skin to a depth of
1–2 mm.30 This is manifestly insufﬁcient for a substantial
number of cases in which Paget cells extend well beyond this.
Whereas data on the presence or absence of invasion are
available in previously published trials, the issue of adnexal
spread has not been properly addressed. Nonetheless, it
has been speculated that therapeutic responses may be related
to the depth of penetration of imiquimod such that thicker
portions of an in situ lesion or tumor with extensive adnexal
involvement or invasive disease may exhibit incomplete
responses.31
Appendages may be colonized by neoplastic cells in
different ways. We noted several patterns of adnexal involve-
ment These include involvement or spread as single cells,
small clusters, gland-like formations, substitution of luminal
cells in ducts/coils with preserved peripheral basal/
myoepithelial cells resulting in ductal carcinoma in situ–like
appearances, or, conversely, predominant replacement of
basal/myoepithelial cells. Additionally, ductal structures
may exhibit epithelial metaplasia and hyperplasia, posing
potential diagnostic pitfalls. We also noted changes in
AGMLG, structures mooted to play a role in the etiology
and pathogenesis of primary EMPD,7,2,3 but these results will
be reported in a separate study.
In conclusion, adnexal involvement in primary EMPD is
a very common feature occurring in more than 90% of cases.
Hair follicles and eccrine ducts are the most commonly affected
adnexa by Paget cells. In this study, the maximal depth of
involvement was as much as 3.6 mm, with the median for
each adnexal structure ranging from 0.93 mm (eccrine ducts) to
2.55 mm (eccrine secretory coils). Given the fact that we used
for formalin-ﬁxed tissues in the study, the actual depth of
invasion in vivo is bound to be deeper. This phenomenon
should be taken into account when planning topical therapy or
developing novel local treatment modalities for EMPD.
FIGURE 8. A duct showing replacement of the basal/my-
oepithelial cells by Paget cells.
FIGURE 9. Infiltration of eccrine coils occasioning a resemblance to either ductal carcinoma in situ or so-called lobular cancer-
ization as seen in mammary carcinomas (A, B).
FIGURE 10. A large complex structure of uncertain derivation
involved by neoplastic cells (A, B). It clearly differs from
hyperplastic eccrine or apocrine units and also from anogenital
mammary-like glands depicted in Figure 11 for comparison.
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FIGURE 11. Anogenital mammary-like gland involved by
carcinoma cells.
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